The CaRi-Heart platform helps detect both atherosclerosis and coronary inflammation based on routine cardiac CT scans. Credit: Caristo Diagnostics.

Caristo Diagnostics is piloting its new CaRi-Heart technology in National Health Service (NHS) hospitals in the UK.

The company is deploying the technology in these hospitals as part of the new coronary artery disease management pathway pilot.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Supported by NHS England, the new pilot is being carried out in five NHS trusts, comprising Liverpool Heart and Chest Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, the University Hospitals of Leicester NHS Trust and Royal Wolverhampton NHS Trust.

In accordance with Nice guidelines, the CaRi-Heart platform analyses cardiac computed tomography angiography (CCTA) scans of patients visiting Rapid Access Chest Pain Clinics.

This analysis enables healthcare professionals to improve their patient’s cardiac risk evaluation for optimising medical management.

Released for the UK and EU markets, the platform can identify both atherosclerosis (plaque) and coronary inflammation based on routine cardiac CT scans.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CaRi-Plaquemodule, which is CaRi-Heart’s newest product component, is a web-based software medical device that helps trained operators analyse CCTA data to characterise and quantify coronary plaque components.

Furthermore, the module helps prepare a report that covers the physical characteristics of coronary plaque driven by artificial intelligence algorithms.

Through the patient-specific Fat Attenuation Index Score, the report of CaRi-Heart quantifies coronary inflammation.

The report also offers the CaRi-Heart Risk, which evaluates the overall eight-year risk of a fatal heart attack.

Caristo Diagnostics CEO Frank Cheng said: “Caristo and our clinical partners are excited about this groundbreaking clinical initiative supported by NHS England.

“We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world.”